Author information
1
Department of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, North Texas VA Health Care System, Dallas VA Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9030, USA; Division of Gastroenterology, North Texas VA Health Care System, Dallas VA Medical Center, 111B1, 4500 South Lancaster Road, Dallas, TX 75216, USA. Electronic address: Khurram.Mazhar2@va.gov.
Abstract
Nonalcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in the United States. The NAFLDsubtype, nonalcoholic steatohepatitis, represents a progressive form of the disease that can lead to cirrhosis, portal hypertension, and hepatocellular carcinoma. NAFLD is a diagnosis of exclusion and is strongly related to obesity and the metabolic syndrome. Although there has been an explosion of exciting therapeutic avenues for NAFLD in recent years, the bedrock of management continues to be lifestyle modification, weight loss, and optimization of metabolic risk factors.